← Back

Innovative Medical Management Co Ltd

Innovative Medical Management Co., Ltd. operates in China's medical services sector. It owns and runs Jianhua Hospital, Kanghua Hospital, Futian Hospital, and Mingzhu Hospital, providing outpatient, inpatient, rehabilitation, and medical examination services. The company also handles supply chain management and procurement of pharmaceuticals, medical consumables, and equipment. Formerly Qianzu Pearl Group Co., Ltd., it changed its name in June 2016 and was founded in 2003, with headquarters in Zhuji, China.

Country
Price · split & dividend adjusted
News & notes moving 002173.CS
002173.CS▼

Innovative Medical's 2026 interim report shows net loss of 52.83 million yuan, widening year-on-year

Innovative Medical released its 2026 interim report, with net profit attributable to the parent company at negative 52.83 million yuan, a loss expansion of 41.47 million yuan compared with the same period last year. The company's total operating revenue was 338 million yuan, down 15.88% year-on-year, and net cash flow from operating activities was negative 2.49 million yuan, down 102.97% year-on-year. The latest gross margin was 1.44%, down 10.62 percentage points from the same period last year, and diluted earnings per share was negative 0.12 yuan.
002173.CS · Capital · Negative Net loss widened to 52.83 million yuan with revenue down 15.88% and gross margin falling to 1.44%
Read original ↗
Jiemian·49dRead more →
Brain-Computer Interface▲impact 4

World's First CE-Certified Brain-Computer Interface Device Lands, Innovative Medical Hits 4-Day 3-Board Streak

The brain-computer interface concept continued its strong momentum in early trading on July 28, with Innovative Medical hitting a 4-day 3-board streak, and Hainan Haiyao, Yanshan Technology, and Thalys Medical hitting the daily limit up. The core catalyst for this rally came from an overseas commercialization milestone: US startup Science Corp.'s retinal chip PRIMA has received EU CE certification, becoming the world's first brain-computer interface device to obtain this certification, and has been approved for sale in 30 European countries. On the domestic front, a Chinese research team unveiled a new EEG signal acquisition device, achieving the world's first cross-regional synchronous EEG signal collection from over a thousand people. The implantable brain-computer interface hand motor function compensation system NEO issued its first prescription in Shanghai and completed the world's first implant surgery. Capital market enthusiasm is high, with total financing in China's brain-computer interface sector exceeding 4.4 billion yuan from January to May 2026, more than doubling the full-year total of last year. A research report from Zheshang Securities pointed out that the market size for brain-computer interface demand in China's serious medical field alone could reach 20 to 60 billion yuan, while the global market is projected to grow from 2.41 billion dollars in 2025 to 12.11 billion dollars in 2035, at a compound annual growth rate of 15.8 percent. Southwest Securities judged that 2026 will be the first year of mass production for brain-computer interfaces, with the industry at the tail end of the introduction phase and on the eve of an explosion.
About megatrends
Brain-Computer Interface › Invasive BCI Systems ▲Regulation
Brain-Computer Interface › Neural Signal Processing & Brain-Mapping Tools ▲Capital
Brain-Computer Interface › Non-invasive BCI & Neurotech ▲Technology
002173.CS · Demand · Positive Hit 4-day 3-board streak as a leader in the brain-computer interface rally, catalyzed by overseas CE certification and domestic milestones.
000566.CS · Demand · Positive Mentioned as hitting daily limit up amid brain-computer interface rally driven by CE certification milestone and positive market outlook.
603716.CG · Demand · Positive Mentioned as hitting daily limit up amid brain-computer interface rally driven by CE certification milestone and positive market outlook.
Read original ↗
21世纪经济·69dRead more →
Brain-Computer Interface▲

Brain-computer interface technology accelerates deployment; Meihao Medical is conducting technical cooperation with domestic downstream clients

Brain-computer interface technology is accelerating its deployment, with related concept stocks showing strong performance. Innovative Medical has achieved three trading sessions with two limit-up moves. Meihao Medical stated that the company is deeply engaged in process exploration and technical cooperation with domestic downstream brain-computer interface clients, fully assisting them in moving from research and development validation to large-scale commercial deployment. Vishee Medical focuses on non-invasive technology routes, committed to building a full-cycle closed-loop system of diagnosis, treatment, and rehabilitation. Haige Communications has released its first self-developed consumer-grade product, the intelligent sleep aid device, which is currently in the market promotion stage.
About megatrends
Brain-Computer Interface › Non-invasive BCI & Neurotech Technology
301363.CS · Demand · Positive Conducting technical cooperation with domestic downstream BCI clients to assist large-scale commercial deployment.
002173.CS · Demand · Positive Achieved two limit-up moves in three sessions, indicating strong investor demand driven by sector enthusiasm.
002465.CS · Technology · Neutral Released first self-developed consumer-grade product, but only in market promotion stage.
688580.CG · Technology · Neutral Mentioned as focusing on non-invasive tech routes, but no specific news event.
Read original ↗
证券时报·70dRead more →
Brain-Computer Interface▲2

A-share brain-computer interface concept stocks surge, multiple stocks hit daily limit

On the morning of July 27, A-share brain-computer interface concept stocks broke out strongly, with stocks in the sector rising collectively during the session. Chuangxin Medical hit a three-day two-board pattern, Aipeng Medical recorded a 20 percent daily limit up, Hainan Haiyao recorded a 10 percent daily limit up and hit a four-day two-board pattern, while Meihao Medical, New Journey, Yingkang Life, Xiangyu Medical, and Sanbo Brain Hospital and other concept stocks followed the rally. On the news front, a Chinese research team recently released a new type of EEG signal acquisition device, achieving for the first time globally the synchronous collection of EEG signals from over a thousand people across different regions. This breakthrough marks a key step forward in neural large model training and general brain-computer interface technology research and development. Kaiyuan Securities stated that it remains bullish on innovative drugs and their industry chain, as well as national strategic emerging industries such as AI, brain-computer interfaces, and biomanufacturing.
About megatrends
Brain-Computer Interface › Non-invasive BCI & Neurotech ▲Technology
300753.CS · Technology · Positive Company is part of brain-computer interface concept stocks that surged on news of a breakthrough in EEG signal acquisition device.
301293.CS · Technology · Positive Company is part of brain-computer interface concept stocks that surged on news of a breakthrough in EEG signal acquisition device.
301363.CS · Technology · Positive Company is part of brain-computer interface concept stocks that surged on news of a breakthrough in EEG signal acquisition device.
000566.CS · Technology · Positive Hit a 10% daily limit up as part of the brain-computer interface concept rally triggered by the EEG device breakthrough.
002173.CS · Technology · Positive Hit a three-day two-board pattern as a brain-computer interface concept stock following the EEG device news.
300143.CS · Technology · Positive Mentioned as a concept stock following the rally driven by the EEG signal acquisition breakthrough.
Read original ↗
中国基金报·70dRead more →
Brain-Computer Interface▲

Harbin Pharmaceutical hits 5th consecutive daily limit, leading innovative drug rally; on-device AI and brain engineering sectors active

In early trading on July 16, Harbin Pharmaceutical hit its fifth consecutive daily limit, making it the stock with the longest winning streak among those still on a streak that day. The innovative drug theme remained strong, with Wanbang Pharmaceutical and Puruis rising over 10 percent. The on-device AI concept heated up, as Green Precision sealed a 20 percent daily limit, and Daoming Optics and Furong Technology also hit their daily limits. On the news front, seven on-device generative AI services completed regulatory filings, and the 2026 World Artificial Intelligence Conference is set to take place in Shanghai. The brain engineering sector saw a sudden surge during the session, with Chuangxin Medical hitting its daily limit in a straight line, and Saili Medical and Aipeng Medical following higher. The world's first implantable brain-computer interface system, NEO, saw its first prescription issued in Shanghai after receiving market approval. Total market turnover exceeded 1.4 trillion yuan, shrinking by 236.7 billion yuan compared with the same period last session, with over 3,200 stocks advancing.
About megatrends
Brain-Computer Interface › Invasive BCI Systems ▲Regulation
Artificial Intelligence › Edge & On-device AI Silicon Regulation
600664.CG · Demand · Positive Harbin Pharmaceutical hit its fifth consecutive daily limit, leading the innovative drug rally.
002173.CS · Technology · Positive Chuangxin Medical hit its daily limit after the world's first implantable BCI system NEO received market approval.
002632.CS · Demand · Positive Daoming Optics hit its daily limit as the on-device AI concept heated up.
300968.CS · Demand · Positive On-device AI concept heats up; Green Precision sealed a 20% daily limit as part of the rally.
603327.CG · Demand · Positive Furong Technology hit its daily limit as the on-device AI concept heated up.
603716.CG · Demand · Positive Wuhan Thalys Med Tech (Puruis) rose over 10% as part of the innovative drug theme.
Read original ↗
上海证券报·81dRead more →
002173.CS▼

Innovative Medical expects a loss of 48 million to 62 million yuan in the first half of 2026

Innovative Medical disclosed its performance forecast, expecting a net loss attributable to the parent company of 48 million to 62 million yuan in the first half of 2026, compared with a loss of 11.3613 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 51 million to 65 million yuan, compared with a loss of 12.8841 million yuan in the same period last year. Basic earnings per share are between negative 0.11 yuan and negative 0.14 yuan. The company stated that the decline in performance was mainly due to factors such as the adjustment of medical insurance policies in the location of Jianhua Hospital and the price reduction from centralized procurement of drugs and consumables.
002173.CS · Regulation · Negative Expects widened net loss due to medical insurance policy adjustment and centralized procurement price cuts.
Read original ↗
中国证券报·83dRead more →